Figure 3

Emmprin expression in endometrial cancer and real-time PCR, western blot, MTS assays and Cell viabilities of HEC-50B and KLE cells after transfection with the emmprin siRNA. A) Western blot analysis of emmprin expression in endometrial cancer cell lines (KLE, Ishikawa, HEC-251, HEC-1A and HEC-50B). An anti-β-actin antibody was used after transfection with the emmprin siRNA. B) Real-time PCR of emmprin expression after transfection of the emmprin siRNA into HEC-50B and KLE cells for 24, 48 and 72 h. C) Western blot analysis of emmprin expression after transfection of the emmprin siRNA into HEC-50B and KLE cells for 72 h. An anti-β-actin antibody was used as a loading control in the same membrane. D) MTS assays of the cell proliferation of HEC-50B and KLE cells after transfection with the emmprin siRNA for 24, 48 and 72 h. The assays were carried out for quadruplicate transfection experiments. E) Cell viabilities of HEC-50B and KLE cells after transfection with the emmprin siRNA for 72 h evaluated by fluorescence microscopy.